BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research note published on Thursday morning,Benzinga reports. They currently have a $25.00 price objective on the stock.

BioCardia Price Performance

Shares of BCDA stock opened at $1.85 on Thursday. The business has a fifty day moving average of $2.58 and a 200 day moving average of $3.31. BioCardia has a 1 year low of $1.84 and a 1 year high of $14.40. The firm has a market capitalization of $3.93 million, a price-to-earnings ratio of -0.44 and a beta of 1.28.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.